Gamma delta T-cell receptor for tumor-associated phosphoantigen recognition (γδ TCR (specifically Vγ9Vδ2 TCR))

The gamma delta T-cell receptor (γδ TCR), particularly the Vγ9Vδ2 subtype, mediates recognition of tumor-associated phosphoantigens—small phosphorylated metabolites that accumulate in tumor cells or during certain infections. Unlike conventional αβ T-cell receptors, γδ TCRs do not depend on peptide antigens presented by classical major histocompatibility complex (MHC) molecules but instead recognize phosphoantigens through a unique presentation mechanism involving butyrophilin family members, primarily BTN3A1 and BTN2A1. BTN3A1 acts as the phosphoantigen sensor inside target (often tumor) cells, while BTN2A1 interacts directly with the Vγ9 region of the TCR to facilitate activation. Drugs such as zoledronate can increase levels of endogenous phosphoantigen, triggering γδ T cell activation and cytotoxicity toward cancer cells. These properties underpin interest in targeting or harnessing γδ T cell responses for cancer immunotherapy. The receptor and its associated butyrophilins play key roles in immune surveillance against transformed and infected cells and offer a non-MHC-dependent mechanism for immunotherapeutic intervention.

Other names

Vγ9Vδ2 T-cell receptorgamma delta TCRVgamma9 Vdelta2 T-cell receptorphosphoantigen-reactive gamma delta T-cell receptorPAg-sensing γδ TCR

Agonist drugs (e.g., zoledronate) increase intracellular phosphoantigen (isopentenyl pyrophosphate, IPP) levels in tumor cells, leading to activation of Vγ9Vδ2 T cells via the γδ TCR and associated butyrophilins (BTN3A1 and BTN2A1).